Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / COM NEW
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
3,032,931
-
Shares change
-
-466,808
-
Total reported value, excl. options
-
$3,425,775
-
Value change
-
-$602,452
-
Put/Call ratio
-
41.6%
-
Number of buys
-
16
-
Number of sells
-
-22
-
Price
-
$1.13
Significant Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2016
58 filings reported holding GALT - GALECTIN THERAPEUTICS INC - COM NEW as of Q3 2016.
GALECTIN THERAPEUTICS INC - COM NEW (GALT) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,032,931 shares
.
Largest 10 shareholders include D.A. DAVIDSON & CO. (602,731 shares), VANGUARD GROUP INC (589,523 shares), Advisor Group, Inc. (413,125 shares), JACOBS LEVY EQUITY MANAGEMENT, INC (139,714 shares), COURAGE CAPITAL MANAGEMENT LLC (130,000 shares), Benchmark Capital Advisors (118,200 shares), GEODE CAPITAL MANAGEMENT, LLC (107,721 shares), KCG Holdings, Inc. (100,958 shares), Neuberger Berman Group LLC (92,519 shares), and US BANCORP \DE\ (90,834 shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.